Difference between revisions of "Enzalutamide"

Revision as of 13:08, 18 March 2019

Enzalutamide is an antrogen receptor antagonist used to treat prostate cancer.^[1]

↑ Mitsiades, N. (Aug 2013). "A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.". Cancer Res 73 (15): 4599-605. doi:10.1158/0008-5472.CAN-12-4414. PMID 23887973.

Revision as of 14:51, 30 May 2016 (view source) Michael (talk \| contribs) ← Older edit		Revision as of 13:08, 18 March 2019 (view source) Michael (talk \| contribs) Newer edit →
Line 1:		Line 1:
	'''Enzalutamide''' is an antrogen receptor antagonist used to treat [[prostate cancer]].<ref name=pmid23887973>{{Cite journal \| last1 = Mitsiades \| first1 = N. \| title = A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. \| journal = Cancer Res \| volume = 73 \| issue = 15 \| pages = 4599-605 \| month = Aug \| year = 2013 \| doi = 10.1158/0008-5472.CAN-12-4414 \| PMID = 23887973 }}</ref>		'''Enzalutamide''' is an [[antrogen receptor]] antagonist used to treat [[prostate cancer]].<ref name=pmid23887973>{{Cite journal \| last1 = Mitsiades \| first1 = N. \| title = A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. \| journal = Cancer Res \| volume = 73 \| issue = 15 \| pages = 4599-605 \| month = Aug \| year = 2013 \| doi = 10.1158/0008-5472.CAN-12-4414 \| PMID = 23887973 }}</ref>

	==See also==		==See also==